Search through
Tenofovir Disoproxil Fumarate (CAS 202138-50-9) is a pivotal nucleotide analog reverse transcriptase inhibitor (NtRTI) dominating the API intermediates market for HIV-1 and chronic Hepatitis B therapeutics. As a bulk chemical supplier, we see high demand for this prodrug in fixed-dose combinations with emtricitabine or efavirenz, where CDMOs require high-purity fine chemicals (Pharma/API purity 99%) to ensure therapeutic efficacy and minimize renal toxicity risks in long-term treatment regimens. TDF (CAS 202138-50-9) remains a cornerstone in the global shift toward pre-exposure prophylaxis (PrEP) and universal access programs, driving significant growth in the generic API sector. Custom synthesis services are increasingly focused on optimizing the fumaric acid salt crystallization process to maintain rigorous regulatory compliance and meet the escalating volume requirements of global sourcing shifts toward audited, GMP-compliant facilities (Pharma/API purity 99%). Bis(isopropyloxycarbonyloxymethyl) [((R)-1-(6-amino-9H-purin-9-yl)propan-2-yloxy)methyl]phosphonate fumarate (CAS 202138-50-9) represents a sophisticated organophosphonate intermediate essential for viral replication inhibition via chain termination. The industry trend toward sustainable manufacturing and robust analytical validation (HPLC/NMR/MS) underscores the necessity for a reliable supplier capable of delivering consistent batches that satisfy FDA and EMA quality standards (Pharma/API purity 99% | General Industry purity 98%). We are an established global API supplier with >= 99% purity for semi-finished formulators, providing comprehensive analytical (HPLC/NMR/MS) and supporting (TENOFOVIR DISOPROX) COA/TDS/SDS region-specific regulatory support, reliable lead times, and worldwide supply chain capabilities.
Tenofovir Disoproxil Fumarate (CAS 202138-50-9) is a pivotal nucleotide analog reverse transcriptase inhibitor (NtRTI) dominating the API intermediates market for HIV-1 and chronic Hepatitis B therapeutics. As a bulk chemical supplier, we see high demand for this prodrug in fixed-dose combinations with emtricitabine or efavirenz, where CDMOs require high-purity fine chemicals (Pharma/API purity 99%) to ensure therapeutic efficacy and minimize renal toxicity risks in long-term treatment regimens. TDF (CAS 202138-50-9) remains a cornerstone in the global shift toward pre-exposure prophylaxis (PrEP) and universal access programs, driving significant growth in the generic API sector. Custom synt...
Chemical Properties & Specifications
P264, P270, P280, P302+P352, P305+P351+P338, P310, P321, P332+P313, P362, P405, and P501
Acute Tox. 4 (100%)
Skin Irrit. 2 (100%)
Tenofovir disoproxil fumarate is a nucleotide reverse transcriptase inhibitor (NRTI) used in combination with other antiretroviral agents to manage HIV-1 infection in adults and pediatric patients at least 2 years of age
The medication is indicated for the treatment of chronic hepatitis B virus (HBV) infection in both adults and pediatric patients, working by inhibiting the viral DNA polymerase enzyme to reduce viral load
When used in fixed-dose combinations with emtricitabine, it is utilized for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in high-risk individuals
Served as a critical advancement in antiretroviral therapy as a prodrug of tenofovir, designed to improve oral bioavailability and membrane permeability for more effective intracellular delivery.
TENOFOVIR DISOPROX, or Tenofovir disoproxil fumarate, is a nucleotide analog reverse transcriptase inhibitor (NtRTI) used to treat HIV-1 infection and chronic hepatitis B
This ingredient is primarily used in the pharmaceutical and healthcare industries for the production of antiviral medications
It is compatible with oral dosage forms such as film-coated tablets and oral powders, as well as experimental gel formulations for microbicides
Standard analytical specifications include CAS number 202138-50-9, high purity (typically ≥98%), and documentation such as COA, TDS, impurity reports, and regulatory compliance documents
Scimplify has capabilities for global distribution and custom synthesis through an integrated network of manufacturers and logistics partners with reliable lead time
The product is export ready with a standard MOQ starting from 100 kgs, with lead times for international customers depending on the specific formulation and destination.
